This expansion of field visit services will help the company become a leading center for psychedelic clinical trials
TORONTO, Dec. 14 2021 (GLOBE NEWSWIRE) – Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) (“Field Trip”), a global leader in the development and delivery of psychedelic therapies, today announced the launch of its Site Management Organization Services (” SMO Services ”). SMO services will enable companies and researchers developing psychedelic therapies to use Field Trip’s world-class facilities and qualified medical and therapy teams to conduct clinical trials. SMO Services will be headed by Stéphan Côté, who joined Field Trip as Quality Manager.
“There are currently over a hundred psychedelic clinical trials in the works or underway, and many more likely, as research into psychedelic therapies continues to accelerate. By adding SMO services, we unlock additional revenue generators from our Field Trip Health centers and play another key role in the future of the psychedelics industry, ”said Joseph del Moral, Co-Founder and CEO of Field Trip. “The setting and setting play a critical role in the positive results that have been demonstrated with psychedelic-assisted psychotherapy. By opening our sites to clinical research, we enable other researchers and organizations to take advantage of our world-class executives and highly qualified staff.
Field Trip currently has offices in seven major US cities, making it one of the largest providers of psychedelic therapy in North America. Since its founding, Field Trip’s focus on pairing and framing with psychotherapy as part of its ketamine-assisted therapy offerings has resulted in improvements for many of its patients, as measured by the Depression Scales. and anxiety, often superior to results generated by IV ketamine infusion centers. .
Côté, who joins Field Trip as a Quality Manager, brings more than 25 years of experience in the field of quality and regulatory compliance. Prior to joining Field Trip, Côté was Director of Quality Assurance at Impel NeuroPharma where he led and supported the development and optimization of Impel’s quality systems and the implementation of commercial quality and compliance systems that enabled the launch of Impel’s first product. Previously, Côté worked for 19 years in several quality assurance roles at Amgen.
In his role with Field Trip, Côté will focus on the development and refinement of Field Trip’s quality systems to strategically align with the rapid advancement of Field Trip’s drug development pipeline and the creation of a network of clinical research and SMO services.
“I am delighted to join Field Trip at such a crucial time in the company’s journey,” said Stéphan Côté, Quality Manager at Field Trip. “I look forward to making Field Trip a premier network of clinical research sites and the partner of choice for researchers, CROs and sponsors in the fields of psychedelic-assisted psychotherapy and other health therapies. mental. We hope to provide the highest quality services with a patient-centric philosophy. The rights, safety and well-being of patients are and always will be our first priority. I believe these research services will align with Field Trip’s mission to help bring solutions to this seemingly overwhelming global mental health crisis. “
About Field Trip Health Ltd.
Field Trip is the world leader in the development and supply of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and leading advanced research in plant-based psychedelics, including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapy. Opening up across North America and Europe with the digital and technological tools that will enable massive scale, we help people in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and scale up engagement with the world.
Follow us on Twitter and Instagram: @fieldtriphealth
To receive company updates on Field Trip and to be added to the email distribution list, please subscribe here.
For more information, contact Ronan Levy, Executive Chairman and Director of Field Trip, at 1 (833) 833-1967.
Caution regarding forward-looking information.
This press release contains forward-looking information (within the meaning of Canadian securities laws and the meaning of the US Private Securities Litigation Reform Act of 1995) concerning Field Trip and its activities. Often, but not always, forward-looking information can be identified by the use of words such as “expect”, “intend”, “anticipate”, “believe” or variations (including negative variations) of such words and expressions, or state that certain actions, events or results “may”, “could”, “would” or “will” be undertaken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances mentioned in this press release may not occur and could differ materially due to known and unknown risk factors and uncertainties affecting businesses, including the start-up, adoption and success of the business. Site Management Organization (SMO) services, timing and results of SMO activities, if applicable, opening of additional clinics that can be used as SMO locations, COVID-19 outbreak, industry medical clinics, market conditions, economics, management’s ability to manage and operate the business and the stock markets in general. Although Field Trip has attempted to identify material factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or or results differ from those anticipated, estimated or intended. Therefore, readers should not place undue reliance on forward-looking statements or information. No forward-looking statement can be guaranteed. Unless required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip assumes no obligation to publicly update or revise any forward-looking statement, whatsoever. either as a result of new information, future events, or otherwise.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
Neither the Toronto Stock Exchange nor its Regulation Services Provider have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
Kathleen Heaney / Tim Regan
KCSA strategic communication
SOURCE Field Trip Health Ltd.